Additionally, the study did not interrogate for notable risk factors for CKD-MBD, including body mass index (Kausz et al., 2005), bone density (Iseri et al., 2020; Pazianas and Miller, 2021), other biomarkers (e.g., FGF-23) (Isakova et al., 2011), bone pathology (Fusaro et al., 2022), and nutrition history/medications (Rysz et al., 2021; Sultana et al., 2015). This evidence concerns the gene FGF23 and Marchiafava-Bignami disease.